Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change

• Published in: Journal of the American Heart Association Vol. 10; no. 17; p. e019434
• Main Authors: Aryal, Sudeep R, Siddiqui, Mohammed, Sharifov, Oleg F, Coffin, Megan D, Zhang, Bin, Gaddam, Krishna K, Gupta, Himanshu, Denney, Jr, Thomas S, Dell'Italia, Louis J, Oparil, Suzanne, Calhoun, David A, Lloyd, Steven G
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 07.09.2021; Wiley
• Subjects: Antihypertensive Agents - therapeutic use; aorta; Blood Pressure - drug effects; Humans; hyperaldosteronism; Hypertension - diagnosis; Hypertension - drug therapy; Original Research; Pulse Wave Analysis; resistant hypertension; spironolactone; Spironolactone - therapeutic use; Vascular Stiffness - drug effects; hyperaldosteronism; aorta; resistant hypertension; spironolactone
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.120.019434

Background Aortic stiffness is an independent predictor of cardiovascular events in patients with arterial hypertension. Resistant hypertension is often linked to hyperaldosteronism and associated with adverse outcomes. Spironolactone, a mineralocorticoid receptor antagonist, has been shown to reduce both the arterial blood pressure (BP) and aortic stiffness in resistant hypertension. However, the mechanism of aortic stiffness reduction by spironolactone is not well understood. We hypothesized that spironolactone reduces aortic stiffness in resistant hypertension independently of BP change. Methods and Results Patients with uncontrolled BP (≥140/90 mm Hg) despite use of ≥3 antihypertensive medications (including diuretics) were prospectively recruited. Participants were started on spironolactone at 25 mg/d, and increased to 50 mg/d at 4 weeks while other antihypertensive medications were withdrawn to maintain constant mean BP. Phase-contrast cardiac magnetic resonance imaging of the ascending aorta was performed in 30 participants at baseline and after 6 months of spironolactone treatment to measure aortic pulsatility, distensibility, and pulse wave velocity. Pulse wave velocity decreased (6.3±2.3 m/s to 4.5±1.8 m/s, <0.001) and pulsatility and distensibility increased (15.9%±5.3% to 22.1%±7.9%, <0.001; and 0.28%±0.10%/mm Hg to 0.40%±0.14%/mm Hg, <0.001, respectively) following 6 months of spironolactone. Conclusions Our results suggest that spironolactone improves aortic properties in resistant hypertension independently of BP, which may support the hypothesis of an effect of aldosterone on the arterial wall. A larger prospective study is needed to confirm our findings.